Literature DB >> 23038273

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.

C Shepherd1, L Banerjee, C W Cheung, M R Mansour, S Jenkinson, R E Gale, A Khwaja.   

Abstract

PI3K, mTOR and NOTCH pathways are frequently dysregulated in T-cell acute lymphoblastic leukaemia (T-ALL). Blockade of PI3K and mTOR with the dual inhibitor PI-103 decreased proliferation in all 15 T-ALL cell lines tested, inducing cell death in three. Combined PI3K/mTOR/NOTCH inhibition (with a γ-secretase inhibitor (GSI)) led to enhanced cell-cycle arrest and to subsequent cell death in 7/11 remaining NOTCH mutant cell lines. Commitment to cell death occurred within 48-72 h and was maximal when PI3K, mTOR and NOTCH activities were inhibited. PI-103 addition led to upregulation of c-MYC, which was blocked by coincubation with a GSI, indicating that PI3K/mTOR inhibition resulted in activation of the NOTCH-MYC pathway. Microarray studies showed a global increase in NOTCH target gene expression upon PI3K/mTOR inhibition. NOTCH-MYC-induced resistance to PI3K/mTOR inhibition was supported by synergistic cell death induction by PI-103 and a small molecule c-MYC inhibitor, and by reduction of the cytotoxic effect of PI-103+GSI by c-MYC overexpression. These results show that drugs targeting PI3K/mTOR can upregulate NOTCH-MYC activity, have implications for the use of PI3K inhibitors for the treatment of other malignancies with activated NOTCH, and provide a rational basis for the use of drug combinations that target both the pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23038273     DOI: 10.1038/leu.2012.285

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  31 in total

Review 1.  Therapeutic modulation of Notch signalling--are we there yet?

Authors:  Emma R Andersson; Urban Lendahl
Journal:  Nat Rev Drug Discov       Date:  2014-05       Impact factor: 84.694

Review 2.  The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.

Authors:  Rui D Mendes; Kirsten Canté-Barrett; Rob Pieters; Jules P P Meijerink
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

Review 3.  MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Authors:  Nandini Dey; Brian Leyland-Jones; Pradip De
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.

Authors:  Noémi Nagy; Melinda Hajdu; Ágnes Márk; Péter Attila Király; Mónika Tóth; Titanilla Dankó; Mónika Csóka; Anna Sebestyén
Journal:  Tumour Biol       Date:  2016-07-29

5.  Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/β-catenin.

Authors:  Jun Yao; Cuijuan Qian; Ting Shu; Xin Zhang; Zhiqiang Zhao; Yong Liang
Journal:  Cancer Biol Ther       Date:  2013-06-14       Impact factor: 4.742

6.  Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.

Authors:  A Lonetti; I L Antunes; F Chiarini; E Orsini; F Buontempo; F Ricci; P L Tazzari; P Pagliaro; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528

7.  Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Authors:  F Buontempo; E Orsini; L R Martins; I Antunes; A Lonetti; F Chiarini; G Tabellini; C Evangelisti; C Evangelisti; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; A Cappellini; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

8.  Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.

Authors:  L M Neri; A Cani; A M Martelli; C Simioni; C Junghanss; G Tabellini; F Ricci; P L Tazzari; P Pagliaro; J A McCubrey; S Capitani
Journal:  Leukemia       Date:  2013-07-29       Impact factor: 11.528

Review 9.  Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Authors:  Sarah D Cramer; Peter D Aplan; Scott K Durum
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

Review 10.  What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.

Authors:  Samuel J Klempner; Andrea P Myers; Lewis C Cantley
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.